{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:09:50Z","timestamp":1774973390034,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40262-025-01616-y","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:45:10Z","timestamp":1770813910000},"page":"595-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging Model-Informed Drug Development to Predict Asciminib Efficacy in Second-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-9130","authenticated-orcid":false,"given":"Sherwin K. B.","family":"Sy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deok Yong","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Darstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohinoor","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Hoch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Grosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"3","key":"1616_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O\u2019Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164\u201372.","journal-title":"N Engl J Med"},{"issue":"5","key":"1616_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ajh.23691","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89(5):547\u201356.","journal-title":"Am J Hematol"},{"key":"1616_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01132","volume":"9","author":"M Bonifacio","year":"2019","unstructured":"Bonifacio M, Stagno F, Scaffidi L, Krampera M, Di Raimondo F. Management of chronic myeloid leukemia in advanced phase. Front Oncol. 2019;9:1132.","journal-title":"Front Oncol"},{"issue":"4","key":"1616_CR4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"20","key":"1616_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205116","volume":"13","author":"T Ono","year":"2021","unstructured":"Ono T. Which tyrosine kinase inhibitors should be selected as the first-line treatment for chronic myelogenous leukemia in chronic phase? Cancers. 2021;13(20):5116.","journal-title":"Cancers"},{"issue":"20","key":"1616_CR6","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1616_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440\u201353.","journal-title":"Leukemia"},{"issue":"7","key":"1616_CR8","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"TH Brummendorf","year":"2022","unstructured":"Brummendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022;36(7):1825\u201333.","journal-title":"Leukemia"},{"issue":"5","key":"1616_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clml.2013.03.018","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk. 2013;13(5):515\u201329.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"1616_CR10","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40262-024-01428-6","volume":"63","author":"M Hoch","year":"2024","unstructured":"Hoch M, Huth F, Manley PW, Loisios-Konstantinidis I, Combes FP, Li YF, et al. Clinical pharmacology of asciminib: a review. Clin Pharmacokinet. 2024;63(11):1513\u201328.","journal-title":"Clin Pharmacokinet"},{"key":"1616_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.","journal-title":"Leuk Res"},{"issue":"10","key":"1616_CR12","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim DW, Kim DDH, Mayer J, Goh YT, et al. Asciminib in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2024;391(10):885\u201398.","journal-title":"N Engl J Med"},{"issue":"21","key":"1616_CR13","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D Rea","year":"2021","unstructured":"Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138(21):2031\u201341.","journal-title":"Blood"},{"issue":"3","key":"1616_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023;37(3):617\u201326.","journal-title":"Leukemia"},{"issue":"5","key":"1616_CR15","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"MJ Mauro","year":"2023","unstructured":"Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. 2023;37(5):1048\u201359.","journal-title":"Leukemia"},{"issue":"10","key":"1616_CR16","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s40262-022-01148-9","volume":"61","author":"YF Li","year":"2022","unstructured":"Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY. Population pharmacokinetics of asciminib in tyrosine kinase inhibitor-treated patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic and acute phases. Clin Pharmacokinet. 2022;61(10):1393\u2013403.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1616_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-025-04755-y","volume":"95","author":"C Darstein","year":"2025","unstructured":"Darstein C, Yoon D, Yang Y, Kapoor S, Dasgupta K, Wu S, et al. Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2025;95(1):39.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1616_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","volume":"69","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, et al. Nilotinib population pharmacokinetics and exposure\u2013response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol. 2013;69(4):813\u201323.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1616_CR19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00228-011-1200-7","volume":"68","author":"RA Larson","year":"2012","unstructured":"Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, et al. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012;68(5):723\u201333.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1616_CR20","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/cpt.2699","volume":"112","author":"FP Combes","year":"2022","unstructured":"Combes FP, Li YF, Hoch M, Lorenzo S, Ho YY, Sy SKB. Exposure-efficacy analysis of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Clin Pharmacol Ther. 2022;112(5):1040\u201350.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"1616_CR21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s40262-024-01411-1","volume":"63","author":"FP Combes","year":"2024","unstructured":"Combes FP, Sy SKB, Li YF, Lorenzo S, Dasgupta K, Kapoor S, et al. Dose justification for asciminib in patients with Philadelphia chromosome-positive chronic myeloid leukemia with and without the T315I mutation. Clin Pharmacokinet. 2024;63(9):1301\u201312.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"1616_CR22","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3324\/haematol.2018.194522","volume":"103","author":"AC Fassoni","year":"2018","unstructured":"Fassoni AC, Baldow C, Roeder I, Glauche I. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. Haematologica. 2018;103(11):1825\u201334.","journal-title":"Haematologica"},{"issue":"10","key":"1616_CR23","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2006","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006;12(10):1181\u20134.","journal-title":"Nat Med"},{"issue":"7046","key":"1616_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435(7046):1267\u201370.","journal-title":"Nature"},{"issue":"35","key":"1616_CR25","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","volume":"30","author":"S Branford","year":"2012","unstructured":"Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012;30(35):4323\u20139.","journal-title":"J Clin Oncol"},{"key":"1616_CR26","doi-asserted-by":"crossref","unstructured":"Sy SKB, Yoon DY, Darstein C, Yang Y, Dasgupta K, Kapoor S, et al. Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model. Br J Clin Pharmacol. 2025;91(5):1419-30.","DOI":"10.1111\/bcp.16381"},{"issue":"38","key":"1616_CR27","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1080\/14796694.2024.2402680","volume":"20","author":"EL Atallah","year":"2024","unstructured":"Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller P, Yang D, et al. Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE phase II trial. Future Oncol. 2024;20(38):3065\u201375.","journal-title":"Future Oncol"},{"key":"1616_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1182\/blood-2024-200717","volume":"144","author":"EL Atallah","year":"2024","unstructured":"Atallah EL, Levy MY, Koller PB, Sasaki K, Tantravahi SK, Andorsky D, et al. Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): interim results from the phase 2 ASC2ESCALATE trial in the cohort of patients (Pts) after 1 prior tyrosine kinase inhibitor (TKI). Blood. 2024;144:479.","journal-title":"Blood"},{"issue":"5","key":"1616_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.12830","volume":"81","author":"CY Zhao","year":"2016","unstructured":"Zhao CY, Jiao Z, Mao JJ, Qiu XY. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2016;81(5):891\u2013907.","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"1616_CR30","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/psp4.12720","volume":"10","author":"PO Hanafin","year":"2021","unstructured":"Hanafin PO, Nation RL, Scheetz MH, Zavascki AP, Sandri AM, Kwa AL, et al. Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients. CPT Pharmacometrics Syst Pharmacol. 2021;10(12):1525\u201337.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1616_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105237","volume":"145","author":"X Cai","year":"2020","unstructured":"Cai X, Li R, Sheng C, Tao Y, Zhang Q, Zhang X, et al. Systematic external evaluation of published population pharmacokinetic models for tacrolimus in adult liver transplant recipients. Eur J Pharm Sci. 2020;145:105237.","journal-title":"Eur J Pharm Sci"},{"issue":"12","key":"1616_CR32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1007\/s00228-021-03193-y","volume":"77","author":"YQ Li","year":"2021","unstructured":"Li YQ, Chen KF, Ding JJ, Tan HY, Yang N, Lin YQ, et al. External evaluation of published population pharmacokinetic models of polymyxin B. Eur J Clin Pharmacol. 2021;77(12):1909\u201317.","journal-title":"Eur J Clin Pharmacol"},{"key":"1616_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1005348","volume":"13","author":"S Huang","year":"2022","unstructured":"Huang S, Ding Q, Yang N, Sun Z, Cheng Q, Liu W, et al. External evaluation of published population pharmacokinetic models of posaconazole. Front Pharmacol. 2022;13:1005348.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1616_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","volume":"6","author":"H Zhou","year":"2015","unstructured":"Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015;6(6):403\u201312.","journal-title":"Protein Cell"},{"issue":"1","key":"1616_CR35","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2018-0008","volume":"7","author":"P Neelakantan","year":"2018","unstructured":"Neelakantan P, Mead A. The transformative journey of chronic myeloid leukemia. Int J Hematol Oncol. 2018;7(1):IJH07.","journal-title":"Int J Hematol Oncol"},{"key":"1616_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106674","volume":"111","author":"CE Ma","year":"2021","unstructured":"Ma CE, Ghosh S, Leyshon C, Blosser N, Dersch-Mills D, Jupp J, et al. Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI. Leuk Res. 2021;111:106674.","journal-title":"Leuk Res"},{"issue":"5","key":"1616_CR37","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s41375-023-01888-y","volume":"37","author":"D Rea","year":"2023","unstructured":"Rea D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, et al. Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial. Leukemia. 2023;37(5):1060\u20137.","journal-title":"Leukemia"},{"issue":"4","key":"1616_CR38","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41375-024-02187-w","volume":"38","author":"S Claudiani","year":"2024","unstructured":"Claudiani S, Chughtai F, Khan A, Hayden C, Fernando F, Khorashad J, et al. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance. Leukemia. 2024;38(4):796\u2013802.","journal-title":"Leukemia"},{"issue":"4","key":"1616_CR39","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141\u20135.","journal-title":"Blood"},{"issue":"9","key":"1616_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841\u201351.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1616_CR41","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123\u20139.","journal-title":"Blood"},{"issue":"8","key":"1616_CR42","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1038\/s41375-020-0805-1","volume":"34","author":"JE Cortes","year":"2020","unstructured":"Cortes JE, Jiang Q, Wang J, Weng J, Zhu H, Liu X, et al. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020;34(8):2064\u201373.","journal-title":"Leukemia"},{"issue":"1","key":"1616_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00280-025-04806-4","volume":"95","author":"SKB Sy","year":"2025","unstructured":"Sy SKB, Yang Y, Darstein C, Yoon DY, Dasgupta K, Kapoor S, et al. Exposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase. Cancer Chemother Pharmacol. 2025;95(1):83.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1616_CR44","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1182\/blood-2024-203757","volume":"144","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Hochhaus A, Hughes TP, Wang J, Kim D-W, Kim DDH, et al. Asciminib (ASC) demonstrates favorable safety and tolerability compared with each investigator-selected tyrosine kinase inhibitor (IS TKI) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the pivotal phase 3 ASC4FIRST study. Blood. 2024;144:475.","journal-title":"Blood"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01616-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:03:17Z","timestamp":1774965797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01616-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1616"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01616-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of Novartis. SKBS, CD, KD, SK MH, and KG own Novartis shares.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This analysis was based on data from patients enrolled in four different trials. All four trials, serving as data sources for this analysis, were approved by the appropriate Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed to the study conceptualization. Data acquisition and analyses were performed by SKBS, DYY, YY, and CD. The first draft of the manuscript was written by SBKS and all authors contributed to the revision of the draft manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Anonymized patient-level data from clinical trials may be shared by Novartis in a consortium called ClinicalStudyDataRequest.com (CSDR) in accordance with Novartis\u2019 policy for sharing clinical trial data (\n                      \n                      ).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}